Table 23.
In vitro inhibition of cancer cell lines growth in leukaemia, NSCLC, colon, CNS, melanoma, renal, and breast cancer subpanels by compounds 18a and b.
| Cell Line | GI50 (µM) a | Cell Line | GI50 (µM) a | ||
|---|---|---|---|---|---|
| 18a | 18b | 18a | 18b | ||
| Leukaemia | CNS Cancer | ||||
| CCRF-CEM | 14.4 | 6.40 | SF-268 | 16.0 | 5.29 |
| HL-60(TB) | 15.4 | 4.45 | SF-295 | 17.1 | 2.52 |
| K-562 | 42.1 | 2.78 | SF-539 | 16.2 | 1.81 |
| MOLT-4 | 4.75 | 1.55 | SNB-19 | 27.0 | 4.09 |
| RPMI82226 | 37.8 | 6.79 | SNB-75 | 18.4 | 4.25 |
| SR | 3.46 | 2.36 | U251 | 12.9 | 3.37 |
| Non-small Cell Lung Cancer | Melanoma | ||||
| A549/ATCC | 16.3 | 3.24 | LOX IMVI | 5.38 | 1.70 |
| EKVX | 27.2 | 3.15 | MALME-3M | 93.1 | 9.64 |
| HOP-62 | 17.3 | 7.98 | M14 | >100 | 2.15 |
| HOP-92 | 2.06 | 1.86 | MDA-MB-435 | ND b | ND |
| NCI-H226 | 19.8 | 5.29 | SK-MEL-2 | 57.5 | 2.34 |
| NCI-H23 | 22.0 | 2.49 | SK-MEL-28 | >100 | 4.80 |
| NCI-H322M | >100 | 5.73 | SK-MEL-5 | 13.1 | 1.79 |
| NCI-H460 | 4.48 | 2.35 | UACC-257 | 80.6 | 4.27 |
| NCI-H522 | 22.1 | 1.75 | UACC-62 | 16.4 | 1.63 |
| Renal Cancer | |||||
| Colon Cancer | 786-0 | 14.1 | 3.41 | ||
| COLO 205 | 7.98 | 2.22 | A498 | 19.6 | 2.44 |
| HCC-2998 | 4.74 | 1.71 | ACHN | 7.67 | 3.23 |
| HCT-116 | 19.0 | 3.82 | CAKI-1 | >100 | 1.70 |
| HCT-15 | 8.68 | 3.01 | RXF 393 | 14.7 | 3.03 |
| HT29 | 5.35 | 3.57 | SN12C | 1.95 | ND |
| KM12 | 4.58 | 3.45 | TK-10 | 37.4 | 5.16 |
| SW-620 | >100 | 3.52 | UO-31 | 37.6 | 3.01 |
| Breast Cancer | |||||
| MCF-7 | 3.95 | 2.64 | |||
| NCI/ADR-RES | 27.6 | 2.25 | |||
| MDA-MB-231/ATCC | 8.06 | 2.95 | |||
| HS 578T | 18.5 | 3.27 | |||
| BT-549 | 15.9 | 2.03 | |||
| T-47D | 79.7 | 4.06 | |||
| MDA-MB-435 | ND | 2.99 | |||
a Concentration (µM) that inhibits 50% net cell growth. b ND = Not Determined.